Unigene appoints Mayes and Pepper to biotechnologies SBU
Unigene Laboratories announced the expansion of its biotechnologies strategic business unit (SBU) with the promotion of Gregory T. Mayes to chief business officer and appointment of Jane Pepper to senior director, business development.
Gregory T. Mayes, Esq. previously held the Unigene position of vice president of corporate development and general counsel, the latter which he will retain with his appointment to chief business officer. Mayes has been an integral part of the turnaround management team that spearheaded Unigene's successful rescue in 2011. He also has been instrumental securing an impressive eight new therapeutic peptide oral drug delivery feasibility studies during the second half of last year.
Jane Pepper, M.B.A, Ph.D., previously was in the development organization of Novartis Pharmaceuticals. She will be responsible for further leveraging Unigene's Peptelligence platform for the oral drug delivery of therapeutic peptides across a broad spectrum of disease areas by continuing to build a robust portfolio of strategically partnered opportunities.